Stay updated on PROMO: Pembrolizumab in Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page.

Latest updates to the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page footer now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe osteosarcoma pembrolizumab trial record is displayed with its study design, eligibility criteria, outcomes, locations, and record history. It indicates the trial was terminated after inclusion stopped because no more than two patients had clinical benefit.SummaryDifference46%

- Check22 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” It does not add information about the clinical trial.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision marker changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the study page still displays a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to PROMO: Pembrolizumab in Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page.